Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

NCT06440005 is registered in ClinicalTrials.gov with Angiex, Inc. as lead sponsor.

NCT NCT06440005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06440005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors
Lead sponsor
Angiex, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 22, 2024
Completion date
September 6, 2027
Enrollment
80 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, angiosarcoma, breast cancer, cancer, colorectal cancer, liver cancer, locally advanced carcinoma, metastatic solid tumor, pancreatic cancer, prostate cancer, solid tumor